Published on

Mark Rogers

Originally published in 2014. Substantially updated and clinically reviewed in 2026.

INTRODUCTION

Prescription opioids and other controlled medications can cause serious harm when misused, but they also have legitimate therapeutic uses. The urgent care clinician must make individualized treatment decisions rather than classify patients by the medications they request.

The drug supply and the care of patients with opioid-related problems have changed substantially since this chapter was originally published. Opioid overdose continues to produce preventable mortality, even as provisional US overdose deaths declined in 2025. Patients who request controlled medications may have untreated pain, interrupted legitimate treatment, physiologic dependence, opioid use disorder (OUD), another substance use disorder, or a combination of these problems. The urgent care clinician must distinguish these conditions without relying on stereotypes and must respond to pain, withdrawal, and overdose risk with professional and compassionate care. (1,2)

PRESENTATION

The presentation of patients requesting controlled medications is quite variable, as might be expected.

Prejudgments and labels are to be avoided at all times because they frequently lead to missed clinical conditions or unfair treatment.

The expression “drug-seeking” describes a behavior or request, not a diagnosis. Requesting a particular medication, reporting severe pain, or asking for a refill does not establish deception, diversion, or OUD. Assess the presenting complaint on its merits. When available and clinically relevant, use the prescription drug monitoring program (PDMP), prior records, and discussion with the patient to clarify the history. An apparently unremarkable PDMP report neither proves nor excludes OUD or exposure to nonprescribed substances. (3)

TRIAGE PEARLS

  • Chief complaints that can be associated with requests for controlled medication:
    • Headache
    • Back pain
    • Dental pain
  • Consider common urgent presentations such as acute injury, abdominal pain, medication interruption, and symptoms of withdrawal. Do not use the chief complaint alone to classify the patient.
  • Requests to consider during triage:
    • Requesting parenteral (IV) narcotic analgesics
    • Scoring >10/10 score on a pain scale
    • Patient out of medications
    • Medication refill request
    • Lost or stolen medications
    • Request of medication by name
  • None of these findings, alone or together, is a validated test for OUD, diversion, or falsified pain. Severe pain and specific medication requests deserve clinical assessment; neither should delay evaluation for a time-sensitive condition.
  • Immediate emergency evaluation is necessary for respiratory depression, hypoxemia, severe sedation, altered mental status, unstable vital signs, suspected overdose, serious infection, acute neurologic deficit, or other potentially life-threatening illness. Provide airway support, activate EMS, and administer naloxone for suspected opioid overdose when indicated.

HISTORY PEARLS

  • Ask about a prior diagnosis of or treatment for a substance use disorder.
  • Determine current use of nonprescribed substances or medications used differently than prescribed.
  • Determine current alcohol use.
  • Ask about all prescribed and nonprescribed medications, alcohol, opioids, benzodiazepines, stimulants, cannabis, and other substances in a neutral manner; include last use, route, dose when known, and previous overdose or withdrawal. Explain that the purpose is safe treatment rather than judgment. (2,4)
  • Clarify the reason for a refill request, previous treatment response, recent changes to the regimen, access barriers, and whether the patient has an established prescribing clinician. Ask permission to contact that clinician or pharmacy when helpful.
  • Co-occurring mood disorders may complicate substance use disorders and pain management; assess both without making assumptions.
  • Ask about depression, anxiety, suicidal thoughts, psychiatric care, and past treatment for substance use disorders when relevant. A psychiatric history should not substitute for an evaluation of the current complaint.
  • The DSM-5-TR diagnosis of OUD requires at least two of 11 criteria in a 12-month period. Examples include:
    • Failure to fulfill major obligations
    • Use when physically hazardous
    • Recurrent social or interpersonal problems
    • Taking larger amounts or for longer than intended; unsuccessful efforts to cut down; craving; time spent obtaining, using, or recovering from opioids; and continuing despite harm.
  • Tolerance and withdrawal alone do not meet the respective DSM-5-TR criteria for OUD when opioids are taken solely under appropriate medical supervision. Mild OUD: 2-3 criteria; moderate: 4-5; severe: 6 or more. (4)
  • Distinguish addiction from physical dependence, which can occur during medically supervised long-term opioid therapy. Document what the patient reports and what can be verified.

PHYSICAL EXAM PEARLS

  • Signs of opioid withdrawal include:
    • Early:
      • Anxiety
      • Insomnia
      • Yawning
      • Lacrimation
      • Diaphoresis
      • Rhinorrhea
      • Diffuse myalgias
    • Late:
      • Piloerection
      • Mydriasis
      • Nausea and vomiting
      • Diarrhea
      • Abdominal cramping
  • Evaluate temperature, pulse, blood pressure, respiratory rate, oxygen saturation, hydration, mentation, and the area relevant to the patient’s complaint. Opioid withdrawal commonly causes autonomic and gastrointestinal symptoms; a patient who appears intoxicated or sedated needs assessment for another immediate risk. (5)
  • Inspect for injection-related infection or other disease when indicated, but do not infer fabrication from appearance, eye contact, pain behavior, or the presence or absence of track marks.
  • If opioid withdrawal is suspected, a structured Clinical Opiate Withdrawal Scale (COWS) examination can help describe withdrawal severity and guide treatment decisions. Evaluate for other medical causes of vomiting, tachycardia, sweating, agitation, or pain. (5)
  • Unlike uncomplicated opioid withdrawal, withdrawal from alcohol or benzodiazepines may cause seizures or other life-threatening complications; suspected significant withdrawal requires emergency evaluation.

TESTING PEARLS

  • Prescription monitoring programs (PMPs)
  • State prescription drug monitoring programs (PDMPs) can be used by the practitioner to review controlled-substance prescriptions. When an opioid is being considered, review the PDMP when feasible, consistent with state requirements. Look for overlapping prescriptions, combinations such as opioids and benzodiazepines, or unexpected patterns. Interpret those findings with the patient and other clinical information; PDMP risk scores are not a diagnosis and should not be used to dismiss a patient from care. (3)
  • Urine screens for drugs of abuse
  • A routine urine immunoassay is not a reliable means of proving or excluding OUD, intoxication, diversion, or an unreported drug exposure. Standard “opiate” assays may not detect fentanyl, buprenorphine, methadone, or some other synthetic and semisynthetic opioids without specific tests. Positive results do not identify dose, timing, impairment, or intent. Consider testing only when the result is likely to change management, discuss unexpected findings nonjudgmentally, and seek confirmatory testing when clinically consequential. (6)
  • Do not delay naloxone, resuscitation, EMS transfer, or other emergency treatment while awaiting a drug-screen result.

DIAGNOSIS PEARLS

  • No single behavior or examination finding is pathognomonic for “drug seeking” or OUD. Coercive or escalating behavior may require a staff safety response, but it is not a diagnostic criterion. The differential includes acute and chronic pain, medication access problems, opioid withdrawal, OUD, other substance use disorders, and medical or psychiatric illness. (3,4)
  • Doctor-shopping refers to actively seeking, from multiple physicians, the same or similar medication within a brief period of time (e.g., 30 days).
  • Multiple prescribers or pharmacies should prompt clarification, not an automatic accusation. Recent surgery, fragmented care, specialty visits, transfers, or insurance disruptions may explain the pattern. Document verifiable prescribing information and the clinical discussion.
  • When OUD is suspected, determine whether DSM-5-TR criteria are met. Document “possible opioid use disorder; further assessment needed” when the information is insufficient for a definitive diagnosis. (4)

TREATMENT AND DISPOSITION PEARLS

  • Tactics to use when confronted with a patient requesting a controlled substance that you are not comfortable prescribing:
    • Remain calm.
    • Explain to the patient that what they requested is not an option.
    • Offer the patient an alternative medication.
    • Demonstrate genuine concern for the patient’s distress, and avoid raising your voice. Also, try to avoid judgmental phrases or tones.
    • Create room for discussion by showing concern and interest for the patient’s well-being.
  • Explain the clinical reasoning for a prescribing decision, acknowledge the patient’s symptoms, and offer an appropriate evaluation, treatment, and follow-up plan. Use clear boundaries rather than bargaining or accusing the patient of addiction.

Pain and other symptoms

  • Evaluate and treat the underlying cause. When appropriate, use acetaminophen, nonsteroidal anti-inflammatory drugs, topical medicines, local anesthesia, and nonpharmacologic measures. Match treatment to the condition; avoid substituting another potentially harmful sedative for an opioid merely because it is not scheduled. (7)
  • Tramadol is an opioid with risks of dependence, misuse, and overdose; it should not be described or prescribed as a nonaddictive alternative. Muscle relaxants and sedating agents require careful consideration, particularly with opioids or benzodiazepines. (3)
  • For insomnia, anxiety, attention-deficit symptoms, or mood disorders, assess the presenting problem and arrange appropriate longitudinal care rather than using a generic medication list designed to replace a requested controlled substance. (7)
  • When opioid analgesia is clinically indicated for acute severe pain, it should not be withheld solely because OUD is suspected. Use an individualized risk-benefit assessment, immediate-release formulations, the lowest effective dose, and no greater quantity than needed for the expected duration; consider naloxone and follow-up. (3)

Opioid withdrawal and opioid use disorder

  • Offer or arrange evidence-based medications for OUD when diagnostic criteria are met, particularly in moderate or severe disease. Buprenorphine and methadone reduce overdose and mortality risk; withdrawal management alone is not adequate treatment for OUD. Methadone for OUD is dispensed through appropriately certified opioid treatment programs. (2,5)
  • Clinicians with appropriate DEA Schedule III authority may prescribe buprenorphine for OUD without the former federal X-waiver, subject to state law and other applicable requirements. If the urgent care has a trained clinician and a reliable follow-up pathway, buprenorphine initiation or bridging may be appropriate; otherwise arrange prompt linkage to treatment. (8)
  • Before buprenorphine initiation, assess clinical withdrawal and recent opioid exposure; starting too early can precipitate withdrawal. Fentanyl exposure may complicate initiation. Use a validated protocol, clinical expertise, and an organized follow-up plan rather than a fixed interval from the last opioid dose. (5,9)
  • For patients unable or unwilling to start medication for OUD during the visit, offer naloxone, explain overdose risks and the loss of tolerance after abstinence, treat current symptoms when safe, and provide an active referral rather than relying on a generic handout. (2,3)
  • Symptoms of uncomplicated opioid withdrawal can be treated supportively with hydration and symptom-directed medications, such as antiemetics or antidiarrheals, when clinically appropriate. Clonidine may help selected patients but requires attention to blood pressure and adverse effects; symptomatic care is not a substitute for OUD treatment. (5)
  • Transfer or refer to an emergency department for suspected overdose, major medical or psychiatric instability, severe dehydration, unsafe withdrawal circumstances, or when the necessary monitoring or treatment cannot be provided in urgent care.

Referral and continuity

  • Referring the patient for treatment:
    • Psychiatry
    • Social work
    • Inpatient and outpatient rehabilitation programs
    • Mutual-help and peer recovery-support programs
  • Community-based recovery support may complement treatment, but should not be substituted for medications for OUD when those are indicated. Use a warm handoff to a clinician or program that can provide medication treatment when possible; SAMHSA’s treatment locator is available at FindTreatment.gov. (2)
  • Dealing with chronic pain: Those patients with chronic, legitimate pain disorders are particularly challenging.
    • Careful monitoring by a primary-care physician
    • Single-pharmacy use
    • Referral to a pain specialist
    • Psychological evaluation
  • Consider coordinated pain care, functional goals, shared decision-making, and medication review. Do not equate long-term prescribed opioid use or physiologic dependence with addiction. For patients already taking opioids long term, abrupt discontinuation can cause harm; coordinate any taper with the longitudinal prescriber. Patients with OUD still deserve effective pain treatment. (3,10)

MEDICOLEGAL PEARLS

  • The federal DATA 2000 X-waiver requirement for prescribing buprenorphine for OUD was removed in December 2022. Prescribers still need appropriate DEA registration, state prescribing authority, and compliance with applicable laws and training requirements. Federal restrictions differ for methadone dispensed for OUD. Verify current state law and clinical policy; the earlier statement that all opioid prescriptions for withdrawal are illegal without a special waiver is incorrect. (8)
  • When a practitioner suspects that a patient is a drug-seeker or is doctor-shopping, careful documentation should be made in the patient’s chart. This includes relevant parts of the medical history and physical exam, laboratory findings, prescription monitoring documentation, and discussions with the patient.
  • Be careful not to label a patient as a drug-seeker, because that could lead to causing undue harm and bias between the patient and future care providers. It is important to remain objective when describing the patient’s behaviors and to cite what alternative treatments (including referrals) have been offered to the patient.
  • Document the diagnostic evaluation, clinical findings, PDMP review when performed, benefits and risks of treatment options, medications given or declined, patient counseling, safety measures, and arranged follow-up. If threats or violence occur, use established staff safety procedures while continuing an appropriate medical evaluation. (3)

REFERENCES

  1. National Center for Health Statistics. U.S. overdose deaths decrease for third consecutive year in 2025. Centers for Disease Control and Prevention. Published May 13, 2026. https://www.cdc.gov/nchs/pressroom/releases/20260513.html
  2. Centers for Disease Control and Prevention. Opioid use disorder: treating. Updated April 9, 2024. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html
  3. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1
  4. Centers for Disease Control and Prevention. Opioid use disorder: diagnosis. Updated April 16, 2024. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-diagnosis.html
  5. Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63. Updated 2021. https://www.samhsa.gov/sites/default/files/pep21-02-01-002.pdf
  6. Stolbach AI, Connors NJ, Nelson LS, Kulig K. ACMT position statement: interpretation of urine opiate and opioid tests. J Med Toxicol. 2022;18(2):176-179. doi:10.1007/s13181-021-00864-1
  7. Centers for Disease Control and Prevention. Nonopioid therapies for pain management. Updated January 31, 2025. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/nonopioid-therapies-for-pain-management.html
  8. Substance Abuse and Mental Health Services Administration. Waiver elimination (MAT Act). https://www.samhsa.gov/substance-use/treatment/resources/mat-act
  9. Agency for Healthcare Research and Quality. Quick start guide to medications for opioid use disorder. https://integrationacademy.ahrq.gov/products/playbooks/moud-playbook/get-started/quick-start-guide
  10. Centers for Disease Control and Prevention. Opioid use disorder and pain management. Updated April 9, 2024. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/oud-pain-management.html
  11. Baehren DF, Marco CA, Droz DE, et al. A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med. 2010;56(1):19-23.
  12. Grover CA, Garmel GM. How do emergency physicians interpret prescription narcotic history when assessing patients presenting to the emergency department with pain? Perm J. 2012;16(3):2-6.
Textbook of Urgent Care Medicine, Chapter 57, The Drug-Seeking Patient
Log In